MedInCell Stock Drops 3.22% Despite a 66% Surge Over the Year
The stock of the Montpellier-based biotech company fell by 3.22% this Monday during the session, to 23.48 euros, amid a significant downturn of the CAC 40. This decline occurs even though the stock still showed a weekly gain of over 1% and maintains an annual performance of more than 66%.
Current Trading Session
In mid-morning trading, MedInCell is trading at 23.48 euros, down 3.22% from last Friday's close of 24.26 euros. The stock is following the downtrend of the Parisian market: the CAC 40 is down 1.13% during the session, while the SBF 120 is down 1.08%. Among comparable pharmaceutical sector stocks, Sanofi is down 1.50% and UCB loses 3.33%, indicating broader selling pressure on the European healthcare sector. Over three months, MedInCell has seen a decline of nearly 14%, although the annual dynamics remain very positive with a gain of 66.41%. The next major event for the company is scheduled for June 16, the date of the annual results publication for the fiscal year 2025-2026, which could be a crucial catalyst for the stock's direction.
Technical Analysis
From a technical standpoint, MedInCell's stock price is above its 20-day (22.59 euros) and 50-day (22.89 euros) moving averages, indicating a short-term upward trend. The crossing of these thresholds in recent weeks had accompanied the stock's rebound, even though the price is now just below its 200-day moving average (23.83 euros), which acts as an intermediate resistance level. The RSI, at 59, remains in the neutral zone, far from overbought or oversold thresholds, suggesting that today's pullback does not yet reflect a pronounced technical imbalance. Within the Bollinger Bands, the stock is positioned in the upper part of the channel, at 67% of the amplitude between the lower bound (19.92 euros) and the upper bound (25.26 euros). The nearest support threshold is at 20.24 euros, while the identified resistance is at 25.12 euros, reflecting a still relatively wide corridor that mirrors the high monthly volatility of the stock, measured at 14.68%.
